As Abbott Labs (ABT) Share Value Rose, Holder Sector Gamma As Lowered Holding

May 26, 2018 - By Ellis Scott

Abbott Laboratories (NYSE:ABT) LogoInvestors sentiment increased to 0.91 in Q4 2017. Its up 0.04, from 0.87 in 2017Q3. It improved, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Commonwealth Of Pennsylvania School Empls Retrmt has 155,693 shares. The Connecticut-based Hartford Inv Mgmt Communications has invested 0.41% in Abbott Laboratories (NYSE:ABT). Rench Wealth Mgmt has invested 1.79% in Abbott Laboratories (NYSE:ABT). 184,994 were reported by Tru Company Of Vermont. Financial Architects invested in 0.1% or 10,682 shares. Moreover, Moneta Grp Inc Invest Advisors Lc has 0.02% invested in Abbott Laboratories (NYSE:ABT). 115,612 are held by Barrett Asset Management Ltd Liability Co. Sta Wealth Mngmt Ltd has invested 0.08% in Abbott Laboratories (NYSE:ABT). Livingston Asset Mgmt (Operating As Southport Management) owns 0.14% invested in Abbott Laboratories (NYSE:ABT) for 6,401 shares. Glenview Bancorporation Trust Dept stated it has 1.7% of its portfolio in Abbott Laboratories (NYSE:ABT). Balyasny Asset Management Ltd Liability holds 0.41% of its portfolio in Abbott Laboratories (NYSE:ABT) for 2.30M shares. Assets Investment Mgmt Ltd Limited Liability Company accumulated 40,500 shares or 0.44% of the stock. Employees Retirement Association Of Colorado holds 1.23 million shares or 0.45% of its portfolio. Shamrock Asset Mngmt Ltd Liability holds 14,412 shares or 0.49% of its portfolio. Optimum Investment Advsrs reported 0.25% in Abbott Laboratories (NYSE:ABT).

Since December 14, 2017, it had 1 buying transaction, and 21 insider sales for $23.88 million activity. Shares for $126,559 were sold by Bracken Sharon J on Monday, March 5. MANNING JOSEPH J also sold $84,344 worth of Abbott Laboratories (NYSE:ABT) shares. Watkin Jared had sold 297 shares worth $17,609 on Friday, February 16. BIRD ROGER also sold $96,728 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, February 28. Salvadori Daniel Gesua Sive had sold 28,319 shares worth $1.56M on Thursday, December 14. On Monday, April 23 the insider Contreras Jaime sold $50,397.

Sector Gamma As decreased its stake in Abbott Labs (ABT) by 15.09% based on its latest 2017Q4 regulatory filing with the SEC. Sector Gamma As sold 191,900 shares as the company’s stock rose 5.88% while stock markets declined. The institutional investor held 1.08M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $61.63M, down from 1.27M at the end of the previous reported quarter. Sector Gamma As who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $109.35B market cap company. The stock decreased 0.22% or $0.14 during the last trading session, reaching $62.37. About 3.84M shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since May 26, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on July, 19. They expect $0.71 earnings per share, up 14.52 % or $0.09 from last year’s $0.62 per share. ABT’s profit will be $1.24B for 21.96 P/E if the $0.71 EPS becomes a reality. After $0.59 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 20.34 % EPS growth.

More news for Abbott Laboratories (NYSE:ABT) were recently published by:, which released: “Federal court hands down $500K judgment against St. Pete man charged in stock scheme” on May 25, 2018.‘s article titled: “3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More” and published on May 24, 2018 is yet another important article.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 14 analysts covering Abbott Laboratories (NYSE:ABT), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Abbott Laboratories has $80.0 highest and $6 lowest target. $69.67’s average target is 11.70% above currents $62.37 stock price. Abbott Laboratories had 20 analyst reports since December 12, 2017 according to SRatingsIntel. The firm earned “Neutral” rating on Tuesday, April 24 by Citigroup. The rating was upgraded by JP Morgan to “Overweight” on Tuesday, January 2. The rating was maintained by JP Morgan with “Overweight” on Thursday, January 25. Wells Fargo maintained it with “Outperform” rating and $70 target in Thursday, January 25 report. The rating was maintained by Guggenheim with “Buy” on Thursday, January 25. The stock has “Buy” rating by BMO Capital Markets on Wednesday, January 24. The firm has “Buy” rating given on Tuesday, January 2 by Guggenheim. The firm has “Buy” rating given on Wednesday, January 24 by RBC Capital Markets. The rating was maintained by Barclays Capital on Thursday, January 25 with “Overweight”. Citigroup maintained Abbott Laboratories (NYSE:ABT) on Tuesday, January 30 with “Neutral” rating.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.